Uncategorized - Rheumatology Advisor


ANA Indicative of Poor Response to bDMARDs in RA

Development of antinuclear antibodies (ANA) could indicate poor response in patients with rheumatoid arthritis (RA) undergoing treatment with biological disease-modifying antirheumatic drugs (bDMARDs), according to a study published in Seminars in Arthritis and Rheumatism. In this prospective single-center cohort study, patients with RA were recruited to determine associations between treatment response and ANA development, during…

Next post in Clinical Charts